Faecal microbioma therapy was discussed at the partner forum
FNUSA-ICRC held its 9th FNUSA-ICRC Partner Forum on May 20, focusing on faecal microbiom therapy and its perspectives. The meeting was attended by over 30 participants from healthcare facilities, research centers and companies specializing in the production, development and research of probiotics and prebiotics or microbiome analysis.
Faecal microbioma therapy represents the therapeutic transfer of faeces in native or processed form from donor to recipient. It is done for the treatment of the recipient, high efficacy is especially proven in the problems caused by Clostridium difficilee. However, according to recent studies, this method is also effective in addressing other diseases, such as nonspecific intestinal inflammation, as participants in the forum have shown.
MUDr. Lenka Vojtilová, Ph.D. From the Clinic of Infectious Diseases of the Faculty Hospital Brno introduces the participants with experience with faecal microbiomic therapy in the treatment of clostridial colitis and new promising indications. A comprehensive view of the microbial settlement of the human body and its relation to human health was introduced by Lenka Micenková Ph.D. from Masaryk University in Brno in a lecture entitled “Dynamics of human microbiome in health and illness”.
A practical view of this issue, namely experience with the use of faecal filtrates in the treatment of idiopathic intestinal inflammation and pseudomembranous colitis, was presented by Janette Čemická from the Institute of Predictive and Personalized Medicine in Bratislava. In the end, PharmDr. Aleš Franc Ph.D. told participants about methods of enteric and colonial administration of drugs and biological material.
The Partner Forum also included an introduction to the FNUSA-ICRC activities and the presentation of the Clinical Studies Department.